Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript Summary
Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript Summary
Operating profit for the quarter was $4.1 million, an improvement from $1.9 million in the previous year. This rise was primarily due to increased gross profit despite higher operating expenses.The following is a summary of the Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript:
以下是Pharming Group N.V.（PHAR）2024年第三季度业绩电话会议交易记录摘要：
Financial Performance:
财务表现：
Q3 revenue increased by 12%, driven by volume growth, especially from RUCONEST, which grew by 6%, and Joenja, which surged by 73%.
Gross profit increased by $9.7 million, aligned with revenue increase, with a slight increase in gross margin.
Operating profit for the quarter was $4.1 million, an improvement from $1.9 million in the previous year. This rise was primarily due to increased gross profit despite higher operating expenses.
Total revenue for the first nine months increased by 25% to $204.5 million. Year-to-date, RUCONEST was up 12% at $172.6 million, and Joenja grew by 210%.
Net loss for the quarter was $1 million compared to a net profit of $3.4 million last year, mainly due to higher finance expenses from adverse euro-dollar exchange rate movements.
第三季度营业收入增长了12%，主要受成交量增长推动，尤其是来自RUCONESt的增长了6%，以及Joenja激增了73%。
毛利润增加了970万美元，与营业收入增加保持一致，毛利率略微增加。
本季度营业利润为410万美元，较上一年的190万美元有所改善。这一增长主要是由于毛利润增加，尽管营业费用较高。
头九个月的总营业收入增长了25%，达到20450万美元。截至目前，RUCONESt的收入增长了12%，达到17260万美元，Joenja增长了210%。
本季度净亏损为100万美元，而去年同期净利润为340万美元，主要是由于欧元兑美元汇率不利的变动导致财务费用增加。
Business Progress:
业务进展：
Pharming Group emphasized their commitment to expanding their commercial footprint, especially in emerging markets like Japan and Australia.
Focused on accelerating patient identification and insurance processes in the U.S., particularly highlighting progress with Joenja, which has captured about 50% of known APDS patients since launch.
Launch preparation for leniolisib outside of the U.S. underway, with significant efforts targeted at the UK and Canada.
Ongoing investments in R&D and clinical trials to leverage commercialization infrastructure and regulatory approvals.
pharming group强调了他们扩大商业版图的承诺，特别是在像日本和澳洲这样的新兴市场。
专注加速美国患者识别和保险流程，特别强调与Joenja的进展，自推出以来已经涵盖了约50%已知的APDS患者。
准备在美国之外推出leniolisib，重点关注英国和加拿大的重要工作正在进行。
持续投资于研发和临床试验，以利用商业化基础设施和监管批准。
Opportunities:
机会：
Strong growth in RUCONEST and Joenja sales underscore opportunities in expanding treatment availability and obtaining regulatory approvals in additional markets, leveraging existing and emerging patient populations.
The potential market expansion with pediatric label extension for Joenja expected by 2026, targeting a patient demographic from age four, highlights significant growth potential.
RUCONESt和Joenja销售的强劲增长突显了在扩大治疗可用性和获得额外市场监管批准方面的机会，利用现有和新兴患者人群。
预计到2026年，Joenja将通过为四岁及以上年龄段的患者推出儿童标签延伸来实现潜在市场扩张，突显了显著的增长潜力。
Risks:
风险：
Challenges in scaling up operations for global market access and the uncertainty surrounding the pace of regulatory approvals especially in new regions like Japan and the UK may pose risks to expected growth trajectories.
The dynamics of Joenja adoption among newly identified APDS patients and the processes of insurance authorizations could impact revenue projections if not managed effectively.
在为全球市场准入扩大业务规模的挑战，以及特别是在日本和英国等新兴市场中监管批准速度的不确定性可能对预期增长路径构成风险。
新鉴定的APDS患者中Joenja采纳的动态以及保险授权流程，如果管理不当，可能会影响营业收入预测。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
